Table 1. Open in new tab...

Table 1.

Clinicopathologic characteristic of NSCLC brain metastases (NSCLC-BM) and primary NSCLC (pNSCLC)

Clinicopathologic characteristics	NSCLC-BM (n = 3035)	n	pNSCLC (n = 7277)	n	P-value
Sex^*					.001
Male	45.4%	1379	49.0%	3567
Female	54.6%	1656	51.0%	3710
Age^**					1.1E−156
Median	62		69
Mean	62.5		68.5
Genetic ancestry^*
African	11.1%	337	9.5%	693	.079
Central and South American	5.5%	168	5.3%	382	1
East Asian	3.4%	103	4.6%	333	.031
European	79.5%	2412	79.9%	5811	1
South Asian	0.5%	15	0.8%	58	.605
Histologic subtype^*
Adenocarcinoma	69.5%	2110	60.4%	4396	1.0E−17
Adenosquamous carcinoma	0.6%	17	0.9%	67	.568
Carcinosarcoma	0.0%	1	0.1%	8	1
Large cell carcinoma	0.5%	15	0.2%	15	.2
Large cell neuroendocrine carcinoma	2.6%	79	1.1%	79	3.9E−07
NOS	19.3%	586	11.2%	818	2.7E−25
Sarcomatoid carcinoma	0.6%	18	0.6%	41	1
Squamous cell carcinoma	6.9%	209	25.5%	1853	3.0E−118
Mutational Signature^*
Tobacco signature	20.2%	614	9.8%	715	1.0E−43

Clinicopathologic characteristics	NSCLC-BM (n = 3035)	n	pNSCLC (n = 7277)	n	P-value
Sex^*					.001
Male	45.4%	1379	49.0%	3567
Female	54.6%	1656	51.0%	3710
Age^**					1.1E−156
Median	62		69
Mean	62.5		68.5
Genetic ancestry^*
African	11.1%	337	9.5%	693	.079
Central and South American	5.5%	168	5.3%	382	1
East Asian	3.4%	103	4.6%	333	.031
European	79.5%	2412	79.9%	5811	1
South Asian	0.5%	15	0.8%	58	.605
Histologic subtype^*
Adenocarcinoma	69.5%	2110	60.4%	4396	1.0E−17
Adenosquamous carcinoma	0.6%	17	0.9%	67	.568
Carcinosarcoma	0.0%	1	0.1%	8	1
Large cell carcinoma	0.5%	15	0.2%	15	.2
Large cell neuroendocrine carcinoma	2.6%	79	1.1%	79	3.9E−07
NOS	19.3%	586	11.2%	818	2.7E−25
Sarcomatoid carcinoma	0.6%	18	0.6%	41	1
Squamous cell carcinoma	6.9%	209	25.5%	1853	3.0E−118
Mutational Signature^*
Tobacco signature	20.2%	614	9.8%	715	1.0E−43

Fisher’s exact test (P-values of genetic ancestry and histologic subtype adjusted with Bonferroni method);

ANOVA.